Ensysce Biosciences, Inc. (LACQ) [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18
	S-1/A	10-K	10-K	10-K/A	10-K
Revenues [+]	2.5	3.5	3.9	0.0	0.6
Net interest income		-1.3	-1.0
Revenue growth	-28.5%	-10.2%		-100.0%
Cost of goods sold	0.0	0.0	0.0	0.0	0.0
Gross profit	2.5	3.5	3.9	0.0	0.6
Gross margin	100.0%	100.0%	100.0%		100.0%
Selling, general and administrative [+]	6.9	18.7	1.2	3.3	1.6
General and administrative	6.9
Research and development	19.8	4.7	4.4
EBITDA [+]		-19.9	-1.6
EBITDA growth	21.9%	1131.8%	-51.5%	247.0%
EBITDA margin	-959.9%	-562.7%	-41.0%		-159.9%
Depreciation and amortization		0.0	0.0
EBIT [+]	-24.2	-19.9	-1.6	-3.3	-1.0
EBIT growth	21.9%	1131.7%	-51.5%	247.0%
EBIT margin	-959.9%	-562.7%	-41.0%		-159.9%
Interest income, net [+]	-0.1			4.2	3.6
Interest expense	0.1	1.2	1.0
Interest income				4.2	3.6
Other income (expense), net [+]	0.1	-8.1	2.4	-1.4	0.0
Gain (loss) on debt retirement		0.2
Change in fair value of warrants				-1.4
Other non-operating income				2.8	3.6
Other	0.1	-0.4		2.8
Pre-tax income	-24.2	-29.1	-0.2	-0.5	2.7
Income taxes	0.0	0.0	0.0	0.6	0.6
Tax rate	0.0%	0.0%	0.0%		20.7%
Minority interest	0.0	-0.1	-0.2
Net income	-25.1	-29.9	0.1	-1.1	2.1
Net margin	-994.1%	-846.4%	1.4%		353.7%

Basic EPS [+]	($139.42)	($1.48)	$0.00	($0.16)	$0.35
Growth	9306.7%	-41269.0%	-102.2%	-145.6%
Diluted EPS [+]	($139.42)	($1.48)	$0.00	($0.16)	$0.35
Growth	9306.7%	-43197.5%	-102.1%	-145.6%

Shares outstanding (basic) [+]	0.2	20.2	15.8	6.6	6.0
Growth	-99.1%	27.9%	138.2%	10.3%
Shares outstanding (diluted) [+]	0.2	20.2	16.5	6.6	6.0
Growth	-99.1%	22.2%	149.3%	10.3%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.